IT1244636B - Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento. - Google Patents

Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.

Info

Publication number
IT1244636B
IT1244636B ITRM910002A ITRM910002A IT1244636B IT 1244636 B IT1244636 B IT 1244636B IT RM910002 A ITRM910002 A IT RM910002A IT RM910002 A ITRM910002 A IT RM910002A IT 1244636 B IT1244636 B IT 1244636B
Authority
IT
Italy
Prior art keywords
treatment
carnitine
acetyl
coma
pharmaceutical compositions
Prior art date
Application number
ITRM910002A
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of ITRM910002A0 publication Critical patent/ITRM910002A0/it
Priority to ITRM910002A priority Critical patent/IT1244636B/it
Priority to ZA9110037A priority patent/ZA9110037B/xx
Priority to JP34691591A priority patent/JP3145451B2/ja
Priority to IE456891A priority patent/IE66025B1/en
Priority to EP91830583A priority patent/EP0498144B1/en
Priority to AT91830583T priority patent/ATE119770T1/de
Priority to ES91830583T priority patent/ES2070478T3/es
Priority to DK91830583.0T priority patent/DK0498144T3/da
Priority to DE69201660T priority patent/DE69201660T2/de
Priority to US07/816,224 priority patent/US5192805A/en
Publication of ITRM910002A1 publication Critical patent/ITRM910002A1/it
Application granted granted Critical
Publication of IT1244636B publication Critical patent/IT1244636B/it
Priority to GR940403979T priority patent/GR3015431T3/el
Priority to HK98104930A priority patent/HK1005847A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Viene descritto l'uso dell'acetil L-carnitina e dei suoi sali farmacologicamente accettabili nel trattamento terapeutico del coma.1000-2000 mg/giorno di acetil L-carnitina o una quantità equivalente di un suo sale farmacologicamente accettabile, vengono somministrati preferibilmente per via parenterale.
ITRM910002A 1991-01-04 1991-01-04 Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento. IT1244636B (it)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ITRM910002A IT1244636B (it) 1991-01-04 1991-01-04 Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
ZA9110037A ZA9110037B (en) 1991-01-04 1991-12-20 The use of acetyl l-carnitine in the therapeutic treatment of coma and pharmacological compositions useful in such treatment
JP34691591A JP3145451B2 (ja) 1991-01-04 1991-12-27 昏睡治療のためのアセチル−ｌ−カルニチンおよび医薬組成物
IE456891A IE66025B1 (en) 1991-01-04 1991-12-30 Use of acetyl L-carnitine in the therapeutic treatment of coma
ES91830583T ES2070478T3 (es) 1991-01-04 1992-01-01 El empleo de acetil l-carnitina en el tratamiento terapeutico de coma.
AT91830583T ATE119770T1 (de) 1991-01-04 1992-01-01 Verwendung von acetyl l-carnitin zur therapeutischen behandlung von coma.
EP91830583A EP0498144B1 (en) 1991-01-04 1992-01-01 Use of acetyl L-carnitine in the therapeutic treatment of coma
DK91830583.0T DK0498144T3 (da) 1991-01-04 1992-01-01 Anvendelse af acetyl-L-carnitin ved terapeutisk behandling af coma
DE69201660T DE69201660T2 (de) 1991-01-04 1992-01-01 Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
US07/816,224 US5192805A (en) 1991-01-04 1992-01-03 Use of acetyl l-carnitine in the therapeutic treatment of coma
GR940403979T GR3015431T3 (en) 1991-01-04 1995-03-16 Use of acetyl L-carnitine in the therapeutic treatment of coma.
HK98104930A HK1005847A1 (en) 1991-01-04 1998-06-05 Use of acetyl l-carnitine in the therapeutic treatment of coma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM910002A IT1244636B (it) 1991-01-04 1991-01-04 Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.

Publications (3)

Publication Number Publication Date
ITRM910002A0 ITRM910002A0 (it) 1991-01-04
ITRM910002A1 ITRM910002A1 (it) 1992-07-04
IT1244636B true IT1244636B (it) 1994-08-08

Family

ID=11399703

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM910002A IT1244636B (it) 1991-01-04 1991-01-04 Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.

Country Status (12)

Country Link
US (1) US5192805A (it)
EP (1) EP0498144B1 (it)
JP (1) JP3145451B2 (it)
AT (1) ATE119770T1 (it)
DE (1) DE69201660T2 (it)
DK (1) DK0498144T3 (it)
ES (1) ES2070478T3 (it)
GR (1) GR3015431T3 (it)
HK (1) HK1005847A1 (it)
IE (1) IE66025B1 (it)
IT (1) IT1244636B (it)
ZA (1) ZA9110037B (it)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1277898B1 (it) * 1995-08-03 1997-11-12 Mendes Srl Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
US5872008A (en) * 1996-02-09 1999-02-16 Bair; Glenn O. Methods for diagnosing pre-menstrual syndrome
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
US5863940A (en) 1997-12-01 1999-01-26 Sigma-Tau Healthscience S.P.A. Medicament and therapeutical method for treating idiopathic asthenozoospermia
SI0951909T2 (sl) 1998-03-19 2010-11-30 Sigma Tau Ind Farmaceuti Kombinirana zmes ki vsebuje L karnitin ali alkanoil L karnitin glikozaminoglikan in ali njegov sestavni del
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
AU2011267186B2 (en) 2010-06-16 2017-01-19 Alfasigma S.P.A. Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
EP2586438A1 (en) 2011-10-28 2013-05-01 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Compound useful for preventing cognitive deficit disorders in a new born from HIV-seropositive pregnant female who is in treatment with azidothymidine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1150396B (it) * 1982-12-09 1986-12-10 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1240760B (it) * 1990-02-12 1993-12-17 Sigma Tau Ind Farmaceuti Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma.

Also Published As

Publication number Publication date
JPH04295424A (ja) 1992-10-20
GR3015431T3 (en) 1995-06-30
EP0498144B1 (en) 1995-03-15
DK0498144T3 (da) 1995-07-24
ITRM910002A0 (it) 1991-01-04
ATE119770T1 (de) 1995-04-15
US5192805A (en) 1993-03-09
DE69201660D1 (de) 1995-04-20
DE69201660T2 (de) 1995-07-20
IE914568A1 (en) 1992-07-15
ZA9110037B (en) 1992-09-30
ITRM910002A1 (it) 1992-07-04
HK1005847A1 (en) 1999-01-29
JP3145451B2 (ja) 2001-03-12
IE66025B1 (en) 1996-01-10
EP0498144A1 (en) 1992-08-12
ES2070478T3 (es) 1995-06-01

Similar Documents

Publication Publication Date Title
IT1244636B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
DE69331409T2 (de) Oral 1alpha-hydroxyprevitamin d
GR1000465B (el) Μεθοδος παρασκευης φαρμακευτικων συνθεσεων που περιεχουν ακετυλ d-καρνιτινη για την θεραπευτικη αγωγη του γλαυκωματος.
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
DK0503440T3 (da) Sumatriptanholdige lægemidler
IT1196564B (it) Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
TR200002207T1 (tr) Slekoksib bileşikleri.
EP0513702A3 (en) Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
IT1235153B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
KR970025615A (ko) 암 전이 억제제
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
GR1000419B (el) Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
DE69412612D1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
ITMI931598A1 (it) Uso terapeutico della fosfocreatina
ES2103422T3 (es) Uso de bilobalida y sus derivados para tratar una infeccion en un individuo y composiciones farmaceuticas destinadas a dicho uso.
RU93052408A (ru) Ациламино-алкилиден-гидрокси-бис-фосфоновые кислоты, способ их получения, фармацевтическая композиция
ITMI931104A1 (it) Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo
UA15281A (uk) Спосіб лікуваhhя хроhічhої ішемічhої хвороби серця
ITRM20010695A1 (it) Uso della propionil l-carnitina o di un suo sale farmacologicamente accettabile per la preparazione di un medicamento per il trattamento del

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19931202